FindTrial
Sign In

A real-world, retrospective, cohort study of ilovolumab in patients with ischemic stroke

A real-world, retrospective, cohort study of ilovolumab in patients with ischemic stroke

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100052777
Enrollment
Unknown
Registered
2021-11-05
Start date
2021-11-30
Completion date
Unknown
Last updated
2022-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic stroke

Interventions

case series:None

Sponsors

Tianjin Medical University General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 87 Years

Inclusion criteria

Inclusion criteria: Aged >= 18 years, started using iloyumab 140 mg/2 weeks or 420 mg/month during hospitalization, and received at least one follow-up visit.

Exclusion criteria

Exclusion criteria: Undergo other drug trials or have any contraindications mentioned in the labeling of ilovolumab.

Design outcomes

Primary

MeasureTime frame
Low density lipoprotein, LDL-C;—

Secondary

MeasureTime frame
Carotid intima thickness;Stenosis degree;—

Countries

China

Contacts

Public ContactSong Yijun

Tianjin Medical University General Hospital

songyj@tmu.edu.cn+86 13012270022

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026